Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatocyte growth factor measurement in AL amyloidosis.
Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A. Abraham J, et al. Among authors: lavergne d. Amyloid. 2015;22(2):112-6. doi: 10.3109/13506129.2015.1014548. Epub 2015 Jun 8. Amyloid. 2015. PMID: 26053104
Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex.
Penot A, Abraham J, Debarri H, Desport E, Aguilar C, Lavergne D, Auroy F, Leleu X, Goldstein A, Kolb B, Bridoux F, Fermand JP, Leblond V, Jaccard A. Penot A, et al. Among authors: lavergne d. Amyloid. 2011 Jun;18 Suppl 1:145-7. doi: 10.3109/13506129.2011.574354054. Amyloid. 2011. PMID: 21838466 Clinical Trial. No abstract available.
Al amyloidosis.
Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales. Desport E, et al. Among authors: lavergne d. Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Orphanet J Rare Dis. 2012. PMID: 22909024 Free PMC article. Review.
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP. Jaccard A, et al. Among authors: lavergne d. Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23. Haematologica. 2014. PMID: 24859879 Free PMC article.
Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T, Jaccard A, Guellich A, Lavergne D, Galat A, Deux JF, Hittinger L, Dupuis J, Frenkel V, Rigaud C, Plante-Bordeneuve V, Bodez D, Mohty D. Damy T, et al. Among authors: lavergne d. Amyloid. 2016 Sep;23(3):194-202. doi: 10.1080/13506129.2016.1221815. Epub 2016 Sep 20. Amyloid. 2016. PMID: 27647161
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G. Palladini G, et al. Among authors: lavergne d. Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024. Clin Chem Lab Med. 2017. PMID: 28343171
Author's reply.
Mohty D, Petitalot V, Magne J, Fadel BM, Boulogne C, Rouabhia D, El Hamel C, Lavergne D, Damy T, Aboyans V, Jaccard A. Mohty D, et al. Among authors: lavergne d. J Cardiol. 2018 Oct;72(4):368. doi: 10.1016/j.jjcc.2018.02.004. J Cardiol. 2018. PMID: 30122209 Free article. No abstract available.
38 results